Vimarsana
Biggest News Aggregation in the World

Page 24 - Topline News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Topline. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Topline Today - Breaking & Trending Today

A sober New Year's Eve at the Jersey Shore - Vimarsana News

A sober New Year's Eve at the Jersey Shore

My wife Jodi and I decided to ring in 2023 with our friends at Copline.org.

Source: nj1015.com
ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease - Vimarsana News

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

Anavex Life Sciences Corp. announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 for the treatment of mild cognitive impairment due to... | December 2, 2022

TauRx Pharmaceuticals Ltd: LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development - Vimarsana News

TauRx Pharmaceuticals Ltd: LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY

Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study - Vimarsana News

Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study

In the cohort of patients enrolled before the age of 30 months, a statistically significant improvement in cognitive development (assessed by BSID-III, Bayley's Scales of Infant Development, third

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect - Vimarsana News

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 ---- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing,... | November 28, 2022